Transarterial chemoembolization outcomes for advanced hepatocellular carcinoma vs sorafenib and best supportive care in a sub-Saharan African cohort

Figure 2 Univariate and multivariate analysis of hazard ratios for patients treated with transarterial chemoembolization using forest plot representation. a: The hazard ratio was calculated by comparing patients in the lowest 10% to those in the highest 90% of the distribution, serving as the reference group; b: The hazard ratio was calculated by comparing patients in the highest 10% to those in the lower 90% of the distribution, serving as the reference group. CI: Confidence interval; HIV: Human immunodeficiency virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; VL: Viral load; CTP: Child-Turcotte-Pugh; MELD-Na: Model of end-stage liver disease-sodium; BCLC: Barcelona Clinic Liver Cancer; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; PVI: Portal vein infiltration; WBC: White cell count; CEA: Carcinoembryonic antigen; CA19.9: Carbohydrate antigen 19-9; AFP: Alpha-fetoprotein; INR: International normalized ratio; ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; C-bilirubin: Conjugated bilirubin; T-bilirubin: Total bilirubin.